Table 23-7.

National Committee for Quality Assurance Health Plan Employer Data and Information Set Measures of Care, 2013

CommercialMedicare
HMOPPOHMOPPOMedicaid (HMO)
AMI
 β-Blocker persistence*83.981.49089.484.2
Cholesterol management for patients with CVD
 LDL-C screening86.782.689.687.981.1
 LDL-C control (<100 mg/dL)57.550.258.656.140.5
BP <140/90 mm Hg64.457.665.562.556.5
DM
 HbA1c testing89.987.392.391.783.8
 HbA1c >9.0%30.537.625.326.645.6
 Eye examination performed55.746.968.56653.6
 LDL-C screening84.981.388.987.776
 LDL-C <100 mg/dL46.740.853.852.733.9
 Monitoring nephropathy84.578.891.189.479.0
 BP <140/90 mm Hg65.058.565.662.260.4
Advising smokers and tobacco users to quit77.370.9N/AN/A75.8
BMI percentile assessment in children and adolescents57.733.2N/AN/A56.9
Nutrition counseling (children and adolescents)56.736.1N/AN/A58.7
Counseling for physical activity (children and adolescents)53.633.8N/AN/A50.5
BMI assessment for adults75.741.489.684.975.9
Physical activity discussion in older adults (≥65 y of age)N/A55.155.2N/A
Physical activity advice in older adults (≥65 y of age)N/A50.448.2N/A
  • Values are percentages. AMI indicates acute myocardial infarction; BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; DM, diabetes mellitus; HbA1c, hemoglobin A1c; HMO, health maintenance organization; LDL-C, low-density lipoprotein cholesterol; N/A, not available or not applicable; and PPO, preferred provider organization.

  • * β-Blocker persistence: Received persistent β-blocker treatment for 6 months after AMI hospital discharge.